Risk factors

The company's risk profile is heavily dominated by its strategic transition to a Gen AI consulting firm and artificial intelligence initiatives.

Horace Mann Educators faces primary concentration risks around targeting and accessing the K-12 educator marketplace for insurance and retirement products. Catastrophe losses, weather events, investment portfolio fluctuations, and interest rate volatility significantly impact financial results. Extensive regulatory oversight, particularly in property and casualty insurance and 403(b) retirement products, shapes operational flexibility.

Company faces concentrated exposure to healthcare sector trends, regulatory changes, and customer renewal rates. Growth depends heavily on successful integration of recent acquisitions like TCPS and The Clinical Hub. Operations are vulnerable to cybersecurity threats, data breaches involving protected health information, and third-party software dependencies.

Water utility operations face heavy rate-setting, environmental, and regional concentration risks in California and Connecticut.

Federal government contracts drive 54% of revenue, making congressional budget approvals and spending priorities critical.

International Flavors & Fragrances faces substantial debt of $8.977 billion and must successfully execute ongoing strategic portfolio divestitures.

Credit risk is concentrated in Massachusetts and broader New England, commercial loans, and real estate collateral.

Inogen relies heavily on Medicare reimbursement and third-party payor policies for portable oxygen concentrator rentals and sales. Single-source suppliers and international contract manufacturing in the Czech Republic create significant supply chain vulnerabilities. Product liability risks center on lithium-ion battery fire hazards in portable oxygen concentrators.

The risk section is dominated by the integration and dual listing of the newly acquired Marel business.

Jasper Therapeutics faces substantial doubt about its going concern status due to recurring net losses and negative operating cash flows. The company is heavily dependent on the clinical success, regulatory approval, and commercialization of its lead product candidate, briquilimab. Operations rely significantly on third-party intellectual property licenses and securing substantial additional financing.

KKR is most exposed to fundraising, investor withdrawals, volatile valuations, leverage, liquidity needs and variable carried-interest earnings.

Kura Oncology faces heavy clinical, regulatory, and financial risks as a pre-revenue biopharmaceutical company with no approved products.